Home
Drugs
Obinutuzumab
Clinical Trials

Clinical Trials Related to Obinutuzumab

Related studies linked through entity extraction aliases.

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Status: COMPLETED
Phase: PHASE1

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Status: COMPLETED
Phase: PHASE3

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Status: RECRUITING
Phase: PHASE3

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Status: TERMINATED
Phase: PHASE1

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Status: RECRUITING
Phase: PHASE2

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

Status: TERMINATED
Phase: PHASE1

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Status: UNKNOWN
Phase: PHASE2

Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)

Status: COMPLETED
Phase: N/A

FT516 in Subjects With Advanced Hematologic Malignancies

Status: TERMINATED
Phase: PHASE1

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Status: TERMINATED
Phase: PHASE2

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Status: TERMINATED
Phase: PHASE1

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3